Compare ConocoPhillips (COP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs IDEXX Laboratories, Inc. — how do they compare? ConocoPhillips trades at $133.93 (market cap $161.21B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: ConocoPhillips is far larger — about 4× IDEXX Laboratories, Inc.'s market cap, and ConocoPhillips pays a 2.5% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| COP | IDXX | |
|---|---|---|
Market Cap | $161.21B | $40.43B |
Volume | 6,058,403 | 692,164 |
Sector | Energy | Health |
52-Week High | $141.22 | $766.68 |
52-Week Low | $85.66 | $504.70 |
Typical Hold Time | 79 Days | 46 Days |
Enterprise Value | $176.81B | $41.32B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% today, with strong technical momentum and bullish moving average signals. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growth from $58.94B in 2025 to projected $63.3B in 2026. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK, signaling strategic portfolio optimization.
COP presents a compelling investment case with solid fundamentals—P/E of 17.75, ROE of 14.14%, and robust cash flow—supported by a 75% analyst buy rating and $154.75 consensus price target. Key risks include geopolitical exposure in the Middle East, oil price volatility, and execution of asset sales. The stock's current level near resistance at $130 suggests near-term consolidation potential amid bullish long-term prospects.
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
